Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Dr. Tsai on Ongoing Research Efforts in Pancreatic Cancer

October 12th 2021, 7:56pm

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

Frontline Bevacizumab/Erlotinib Continues to Impress in EGFR-Mutated NSCLC

September 23rd 2021, 2:00pm

ESMO Congress

The addition of bevacizumab to erlotinib continued to provide a significant progression-free survival benefit over erlotinib alone when used in the frontline treatment of patients with EGFR-mutated, nonsquamous non–small cell lung cancer, according to data from the final analysis of the phase 3 BEVERLY trial.

Regorafenib Confers No PFS Benefit in Advanced Chordoma

September 22nd 2021, 7:00pm

ESMO Congress

Regorafenib did not show a benefit with progression-free survival in patients with advanced or metastatic chordoma.

Acalabrutinib, Alone or With Obinutuzumab, Improves Quality-Adjusted Survival in Frontline CLL

September 22nd 2021, 3:10pm

International Workshop on CLL

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.

Real-World PFS Benefit Reported With Durvalumab Regimen in Unresectable Stage III NSCLC

September 21st 2021, 10:05pm

ESMO Congress

The median real-world progression-free survival with durvalumab was higher compared with the median progression-free survival reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

High HER2 Expression Is Linked With Improved Outcomes With Trastuzumab Deruxtecan in HER2+ mCRC

September 21st 2021, 9:40pm

ESMO Congress

Fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels in patients with HER2-positive, metastatic colorectal cancer.

Dr. Thompson on the Results of the BRUIN Study in Patients With Richter's Transformation

September 21st 2021, 9:37pm

International Workshop on CLL

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

Dr. Robak on the Results of the 7-Year Follow-Up of RESONATE-2 in CLL

September 21st 2021, 9:30pm

International Workshop on CLL

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Adavosertib Improves PFS in RAS-/TP53-Mutant Metastatic Colorectal Cancer

September 21st 2021, 7:27pm

ESMO Congress

Adavosertib demonstrated a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with TP53-/RAS-mutant metastatic colorectal cancer following first-line chemotherapy.

Durvalumab Plus Chemotherapy Showcases Sustained OS Benefit in ES-SCLC

September 21st 2021, 5:11pm

ESMO Congress

The addition of durvalumab to platinum/etoposide chemotherapy continued to demonstrate an overall survival benefit over chemotherapy alone with a favorable safety profile in patients with extensive-stage small cell lung cancer.

Giredestrant Induces Greater Ki-67 Suppression Vs Anastrozole in ER+/HER2– Early Breast Cancer

September 21st 2021, 3:50pm

ESMO Congress

Giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole in patients with estrogen receptor–positive, HER2-negative early breast cancer, according to results from an interim analysis of the phase 2 coopERA Breast Cancer trial.

Tailoring Therapy for Breast Cancer in 2021: Examining and Applying Clinical Lessons

September 21st 2021, 3:29pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Personalized medicine has come to the forefront of breast cancer management, with genomic tools being utilized to avoid unnecessary chemotherapy in those with early-stage disease, PARP and PI3K inhibitors improving outcomes for those who harbor select mutations, and the emergence of highly active targeted agents shaking up the HER2-positive paradigm.

Dr. John Byrd Presented the Binet-Rai Medal Award at XIX International Workshop on Chronic Lymphocytic Leukemia

September 21st 2021, 2:24pm

International Workshop on CLL

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

Sitravatinib/Nivolumab Combo Results in Durable Response in Advanced NSCLC Following Checkpoint Inhibitors, Chemotherapy

September 21st 2021, 1:14pm

ESMO Congress

Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Blood-Based TMB Is Not Predictive of Benefit With Atezolizumab in NSCLC

September 21st 2021, 1:14pm

ESMO Congress

Blood-based tumor mutational burden does not predict a benefit of first-line atezolizumab over chemotherapy in patients with non–small cell lung cancer.

U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richter’s Transformation

September 20th 2021, 10:10pm

International Workshop on CLL

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

Dr. Goy on the Importance of Refined Decision Making With Precision Medicine

September 20th 2021, 9:42pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

Dr. Marshall on the Importance of Molecular Profiling When Utilizing Precision Medicine

September 20th 2021, 9:37pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Dr. Levy on Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC

September 20th 2021, 9:25pm

PER® Precision Medicine Symposium: An Illustrated Tumor Board

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLL

September 20th 2021, 9:23pm

International Workshop on CLL

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.